Tirzepatide Cuts Post-PCI Mortality by 62% in T2D Patients (SCAI Montreal 2026)

Important Notice: This article is intended exclusively for scientific information and research purposes. All substances mentioned are not intended for human consumption. Always consult qualified professionals before using peptides.

Introduction: A Late-Breaking Cardio Signal in Montreal

On 23 April 2026, at the Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions in Montreal, a late-breaking presentation introduced the strongest real-world cardiovascular signal yet for tirzepatide. Lead author Revati Varma, an internal medicine resident at Cook County Hospital in Chicago, reported that adults with type 2 diabetes who received tirzepatide after a percutaneous coronary intervention (PCI) had a 62% lower risk of all-cause mortality at one year compared with patients on dulaglutide (RR 0.38; p<0.001). Major adverse cardiovascular events (MACE) fell by 54% (RR 0.46; p<0.001).

The data, drawn from a retrospective TriNetX cohort of 1,281 propensity-matched patients, position tirzepatide not merely as a metabolic agent but as a candidate for active secondary cardiovascular protection in one of the highest-risk groups in cardiology. The signal extends well beyond the previously reported SURPASS-CVOT outcomes and prompts a fresh look at how the GIP arm of tirzepatide may contribute to vascular and myocardial recovery.

What Is PCI and Why This Cohort Matters

Percutaneous coronary intervention (PCI) is the catheter-based revascularisation procedure used to treat acute coronary syndromes and severe stable angina. A guidewire is advanced through a peripheral artery to the coronary lesion, balloon angioplasty is performed and a drug-eluting stent is typically deployed. PCI is one of the most common invasive cardiology procedures worldwide.

Patients with type 2 diabetes who require PCI carry a disproportionate risk burden. Compared with non-diabetic patients they have:

Higher rates of restenosis and target lesion failure
More diffuse coronary disease with smaller vessels and longer lesions
Higher one-year mortality, frequently in the 6 to 10% range in observational series
Higher rates of heart failure, recurrent infarction and ventricular arrhythmias
Worse glycaemic and inflammatory profiles that impair endothelial healing

Any therapy that materially reduces mortality in this group is clinically significant. Aspirin, dual antiplatelet therapy, statins and SGLT2 inhibitors all earned their place in guidelines on smaller relative risk reductions than the SCAI 2026 dataset shows.

Study Design

The Varma group did not run a prospective randomised trial. They queried the TriNetX research network, a federated electronic health record platform that aggregates de-identified data from dozens of US health systems, for adults with type 2 diabetes who underwent PCI and were subsequently exposed to either tirzepatide or dulaglutide.

Key design features:

Cohort size: 1,281 patients after propensity-score matching
Active comparator: dulaglutide, a once-weekly GLP-1 receptor agonist, rather than placebo
Time points: outcomes assessed at one month and one year after PCI
Matching: propensity scores controlled for age, sex, comorbidities, prior infarction, ejection fraction, baseline HbA1c and concomitant medications
Design: retrospective cohort study, not a randomised controlled trial

The choice of dulaglutide as comparator is methodologically important. It removes most of the GLP-1 class effect from the estimate and isolates the marginal benefit of tirzepatide's dual GIP plus GLP-1 mechanism. A placebo-controlled comparison would have been confounded by the fact that any GLP-1 agonist already lowers cardiovascular risk; the tirzepatide minus dulaglutide contrast is therefore a cleaner test of the dual-incretin hypothesis.

Results

The headline number is striking. At one year after PCI, tirzepatide-treated patients had a relative risk of all-cause mortality of 0.38 versus dulaglutide, equivalent to a 62% reduction (p<0.001). Across the prespecified secondary endpoints the pattern was consistent and large in magnitude:

Endpoint (one year post-PCI)	Relative Risk	Reduction	p-value
All-cause mortality	0.38	62%	<0.001
MACE composite	0.46	54%	<0.001
Acute myocardial infarction	0.47	53%	<0.001
Heart failure exacerbation	0.54	46%	<0.001
Ventricular arrhythmias	0.56	44%	0.03
Stroke	0.56	44%	0.01
Cardiac arrest	0.32	68%	<0.001

The MACE benefit was already detectable at one month and was sustained through the one-year analysis, suggesting both an early and a durable mechanism. The 68% reduction in cardiac arrest is particularly notable because that endpoint is dominated by sudden arrhythmic death, which is poorly modified by glucose-lowering alone.

How Tirzepatide Differs from Pure GLP-1 for Cardiovascular Protection

Tirzepatide is a unimolecular dual agonist of the GIP and GLP-1 receptors. Dulaglutide, semaglutide and liraglutide engage only the GLP-1 receptor. The mechanistic question is whether the additional GIP arm contributes anything cardiovascularly distinct or whether the benefit is simply downstream of greater weight loss and HbA1c reduction.

Three lines of evidence are relevant in 2026:

1. SELECT (semaglutide)

The SELECT trial (NEJM 2023) demonstrated a 20% reduction in MACE with semaglutide 2.4 mg in non-diabetic patients with established cardiovascular disease. This established the GLP-1 class as cardio-protective independent of glucose lowering, but the absolute risk reduction was modest and mortality alone did not reach significance.

2. SURPASS-CVOT (tirzepatide)

SURPASS-CVOT, reported in 2025, showed non-inferiority of tirzepatide versus dulaglutide for MACE in T2D and a numerical advantage that did not cross the superiority threshold in the overall population. The trial was not statistically powered to detect superiority.

3. SCAI 2026 (this dataset)

The Varma cohort selects a much sicker, post-PCI sub-population in which the absolute event rate is higher. In such groups the effect size of an active drug is mathematically amplified. The 62% mortality reduction is consistent with a real biological advantage of dual GIP plus GLP-1 over GLP-1 alone, but it could also reflect residual confounding that propensity matching does not fully capture.

Plausible biology behind a GIP-arm contribution includes:

Endothelial GIP receptor signalling, which improves nitric oxide availability in animal models
Adipose-tissue effects that lower circulating free fatty acids and improve diastolic function
Stronger weight and HbA1c reductions with tirzepatide than with dulaglutide, which translate into better post-stent vascular healing

For a deeper mechanistic discussion see Tirzepatide: Science 2026, the GLP-1 Agonists Compared overview and the Triple Agonist GLP-1/GIP/Glucagon deep dive.

Limitations

The authors of the SCAI presentation explicitly called for prospective trials to confirm the result, and several methodological caveats should temper interpretation:

Retrospective design: The dataset is observational. Even with propensity matching, unmeasured confounders such as socio-economic status, statin adherence and frailty can drive part of the effect.
Healthy-user bias: Patients prescribed the newer, more expensive tirzepatide may differ systematically from patients prescribed dulaglutide. They may be healthier, more adherent or under more attentive cardiology follow-up.
Active comparator floor: Dulaglutide already reduces cardiovascular risk (REWIND trial). Comparison against a true cardiovascular placebo would be ethically difficult but would have shown an even larger absolute benefit.
TriNetX data quality: Federated EHR data are heterogeneous in coding accuracy, especially for soft endpoints such as heart failure exacerbation and ventricular arrhythmia.
Effect size: A 62% mortality reduction is at the upper end of what is biologically plausible for any single pharmacological intervention. Replication is essential.

A definitive answer will likely come from a dedicated post-PCI randomised controlled trial, which has now been openly proposed by several interventional cardiology groups in response to this dataset.

What This Means for the GLP-1 Cardio-Protection Story in 2026

Five years ago the GLP-1 class was a diabetes story. Three years ago it became a weight loss story. In 2026 it is becoming a cardiovascular story. The SCAI 2026 result fits a broader pattern emerging from SELECT, FLOW (kidney), STEP-HFpEF (heart failure with preserved ejection fraction) and now this post-PCI dataset: incretin-based therapies appear to remodel cardiovascular risk in ways that are not fully explained by weight or glucose.

The implication for the wider research field is that mechanistic dissection now matters as much as new compounds. The contrast between dulaglutide and tirzepatide in the SCAI cohort is the clearest real-world signal yet that the dual GIP plus GLP-1 architecture may add cardiovascular benefit on top of the GLP-1 backbone. Triple agonists such as retatrutide, which add a glucagon arm, are the next frontier. See Retatrutide vs Tirzepatide vs Semaglutide for a side-by-side overview.

Conclusion and Takeaways

The SCAI Montreal 2026 late-breaking presentation by the Varma group provides the largest real-world cardiovascular signal for tirzepatide outside of formal CVOT data. In 1,281 post-PCI patients with type 2 diabetes, tirzepatide was associated with a 62% lower one-year mortality, a 54% lower MACE rate and consistent reductions across infarction, heart failure, arrhythmia and cardiac arrest, all benchmarked against dulaglutide as an active comparator.

Key findings:

62% reduction in all-cause mortality at one year (RR 0.38)
54% reduction in MACE (RR 0.46)
68% reduction in cardiac arrest (RR 0.32)
Cohort of 1,281 propensity-matched T2D patients post-PCI
TriNetX retrospective design, presented at SCAI 2026

Open questions:

Replication in a prospective randomised post-PCI trial
Mechanistic dissection of the GIP contribution
Whether the result extends to non-diabetic post-PCI patients

For researchers, this dataset reinforces the thesis that incretin-based therapies are entering cardiology as primary protective agents rather than as metabolic adjuncts. The next twelve months will tell whether the 62% number survives prospective replication, but the direction of travel is clear.

Sources

Varma R, et al. "Tirzepatide vs Dulaglutide in Patients with Type 2 Diabetes Following Percutaneous Coronary Intervention." Late-breaking presentation, SCAI Scientific Sessions, Montreal, 23 April 2026.
SCAI 2026 press release. "Tirzepatide associated with 62% lower mortality post-PCI in adults with type 2 diabetes." EurekAlert, 23 April 2026. https://www.eurekalert.org/news-releases/1125025
Lincoff AM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes (SELECT)." New England Journal of Medicine, 2023.
Nissen SE, et al. "SURPASS-CVOT: Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular Events in Type 2 Diabetes." 2025.